The first patient has been treated in a first-in-human clinical trial investigating the safety and efficacy of the CXLens ...
Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.
Please provide your email address to receive an email when new articles are posted on . An epithelium-on cross-linking procedure from Glaukos delivers oxygen to the eye during treatment. In a study, ...
Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
Patients in Somerset with keratoconus, an eye condition that causes blurred vision and sensitivity to light, can now access ...
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, ...
Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results